GlassScriptPhysician profile
Serena Tidwell
NPI 1033141031
$15,581.75
in general payments reported to CMS, 2019-2025
32 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $3,200 · 2021: $8,612 · 2022: $626 · 2023: $2,146 · 2024: $78.33 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,471 · Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,471.14 |
| Food and Beverage | $965.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,728.83 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $1,946.05 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $567.16 | 2019-2025 | Novasure, Aptima |
| Lupin INC. | $191.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.86 | 2019-2024 | |
| Pfizer INC. | $173.72 | 2021-2023 | |
| Coopersurgical, INC. | $121.71 | 2021-2022 | |
| Asensus Surgical, INC. | $99.57 | 2019 | |
| Therapeuticsmd, INC. | $61.63 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $52.19 | 2021 | |
| Myovant Sciences INC. | $51.15 | 2021 | |
| Myriad Women'S Health, INC. | $47.67 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $32.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.32 | 2022 | |
| Medtronic, INC. | $27.98 | 2023 | Interstim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $26.46 | 2020-2021 | |
| Organon LLC | $26.37 | 2024 | |
| Biogen, INC. | $26.08 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $19.56 | 2025 | Veozah |
| Optumhealth Care Solutions, LLC | $19.03 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Meditrina | $18.09 | 2019 | |
| Minerva Surgical, INC | $17.61 | 2022 | |
| Scynexis, INC. | $17.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.92 | 2023 | |
| Novo Nordisk INC | $16.36 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $14.61 | 2025 | |
| Lilly USA, LLC | $14.28 | 2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $13.74 | 2025 | Contrave, Onzetra Xsail |
| Boston Scientific Corporation | $12.91 | 2019 | |
| Allergan, INC. | $11.61 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Tidwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.